


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:46Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406064" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406064</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406064</article-id><article-id pub-id-type="pmcid-ver">PMC12406064.1</article-id><article-id pub-id-type="pmcaid">12406064</article-id><article-id pub-id-type="pmcaiid">12406064</article-id><article-id pub-id-type="pmid">40892412</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2025.29427</article-id><article-id pub-id-type="publisher-id">zoi250830</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Psychiatry</subject></subj-group></article-categories><title-group><article-title>Measurement-Based Care to Enhance Antidepressant Treatment Outcomes in Major Depressive Disorder</article-title><subtitle>A Randomized Clinical Trial</subtitle><alt-title alt-title-type="headline">Measurement-Based Care to Enhance Outcomes in Major Depressive Disorder</alt-title><alt-title alt-title-type="running-head">Measurement-Based Care to Enhance Outcomes in Major Depressive Disorder</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Husain</surname><given-names initials="MI">Muhammad Ishrat</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250830aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nigah</surname><given-names initials="Z">Zahra</given-names></name><degrees>MPhil</degrees><xref rid="zoi250830aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ansari</surname><given-names initials="SUH">Sami Ul Haque</given-names></name><degrees>MSc</degrees><xref rid="zoi250830aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khoso</surname><given-names initials="AB">Ameer B.</given-names></name><degrees>MSc</degrees><xref rid="zoi250830aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kiran</surname><given-names initials="T">Tayyeba</given-names></name><degrees>PhD</degrees><xref rid="zoi250830aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Umer</surname><given-names initials="M">Madeha</given-names></name><degrees>MSc</degrees><xref rid="zoi250830aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="zoi250830aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ansari</surname><given-names initials="MA">Moin A.</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhatia</surname><given-names initials="MR">Moti Ram</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khan</surname><given-names initials="SA">Sylvia A.</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Husain</surname><given-names initials="MO">Muhammad Omair</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250830aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Malik</surname><given-names initials="AG">Abdul Ghafoor</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Naqvi</surname><given-names initials="HA">Haider Ali</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qadir</surname><given-names initials="A">Altaf</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rajput</surname><given-names initials="AH">Aatir H.</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saqib</surname><given-names initials="M">Mohsin</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ilyas</surname><given-names initials="M">Muhammad</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doutani</surname><given-names initials="MUK">Mujeeb Ullah Khan</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sherzad</surname><given-names initials="S">Silsila</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Siddiqui</surname><given-names initials="KMS">K. M. Sajjad</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tahir</surname><given-names initials="Z">Zona</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="W">Wei</given-names></name><degrees>PhD</degrees><xref rid="zoi250830aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250830aff12" ref-type="aff">
<sup>12</sup>
</xref><xref rid="zoi250830aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Husain</surname><given-names initials="N">Nusrat</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff14" ref-type="aff">
<sup>14</sup>
</xref><xref rid="zoi250830aff15" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chaudhry</surname><given-names initials="N">Nasim</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chaudhry</surname><given-names initials="IB">Imran Bashir</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="zoi250830aff14" ref-type="aff">
<sup>14</sup>
</xref><xref rid="zoi250830aff16" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Mulsant</surname><given-names initials="BH">Benoit H.</given-names></name><degrees>MD</degrees><xref rid="zoi250830aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi250830aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="zoi250830aff1"><label>1</label>Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</aff><aff id="zoi250830aff2"><label>2</label>Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada</aff><aff id="zoi250830aff3"><label>3</label>Pakistan Institute of Living and Learning, Karachi, Pakistan</aff><aff id="zoi250830aff4"><label>4</label>Liaqat University of Medical &amp; Health Sciences, Cowasjee Jehangir Institute of Psychiatry, Hyderabad, Pakistan</aff><aff id="zoi250830aff5"><label>5</label>Department of Psychiatry, Peoples University of Medical and Health Sciences, Shaheed Benazirabad, Pakistan</aff><aff id="zoi250830aff6"><label>6</label>Department of Psychiatry, North West General Hospital, Peshawar, Pakistan</aff><aff id="zoi250830aff7"><label>7</label>Department of Psychiatry, Benazir Bhutto Hospital, Rawalpindi, Pakistan</aff><aff id="zoi250830aff8"><label>8</label>Department of Psychiatry, Dow University of Health Sciences, Karachi, Pakistan</aff><aff id="zoi250830aff9"><label>9</label>Pakistan Institute of Living and Learning, Lahore, Pakistan</aff><aff id="zoi250830aff10"><label>10</label>Baluchistan Institute of Psychiatry and Behavioral Sciences, Quetta, Pakistan</aff><aff id="zoi250830aff11"><label>11</label>Department of Psychiatry, National Psychiatric Hospital, Multan, Pakistan</aff><aff id="zoi250830aff12"><label>12</label>Department of Psychological Clinical Science, University of Toronto Scarborough, Toronto, Ontario, Canada</aff><aff id="zoi250830aff13"><label>13</label>Department of Biostatistics and Data Science, University of South Florida, Tampa</aff><aff id="zoi250830aff14"><label>14</label>Division of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, United Kingdom</aff><aff id="zoi250830aff15"><label>15</label>Mersey Care National Health Service Foundation Trust, Liverpool, United Kingdom</aff><aff id="zoi250830aff16"><label>16</label>Department of Psychiatry, Ziauddin University, Karachi, Pakistan</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> June 7, 2025.</p><p content-type="published-online"><bold>Published:</bold> September 2, 2025. doi:<uri content-type="doi">10.1001/jamanetworkopen.2025.29427</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2025 Husain MI et al. <italic toggle="yes">JAMA Network Open</italic>.</p><corresp id="zoi250830cor1"><bold>Corresponding Authors:</bold> Muhammad Ishrat Husain, MD, Centre for Addiction and Mental Health, 1025 Queen St W, Toronto, ON M6J 1H1, Canada (<email xlink:href="Ishrat.husain@camh.ca">Ishrat.husain@camh.ca</email>); Benoit H. Mulsant, MD, Department of Psychiatry, University of Toronto, 250 College St, #835, Toronto, ON, M5T 1R8, Canada (<email xlink:href="benoit.mulsant@utoronto.ca">benoit.mulsant@utoronto.ca</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr M. I. Husain had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs I. Chaudhry and Mulsant are joint senior authors.</p><p><italic toggle="yes">Concept and design:</italic> M. I. Husain, Nigah, Umer, M. Ansari, Naqvi, Ilyas, Sherzad, N. Husain, N. Chaudhry, I. Chaudhry, Mulsant.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> M. I. Husain, Nigah, S. Ansari, Khoso, Kiran, Umer, M. Ansari, Bhatia, Khan, M. O. Husain, Malik, Qadir, Rajput, Saqib, Doutani, Siddiqui, Tahir, Wang, Mulsant.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> M. I. Husain, Khoso, Umer, M. Ansari, Bhatia, M. O. Husain, Malik, Qadir, Saqib, Ilyas, Doutani, N. Chaudhry, I. Chaudhry, Mulsant.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> M. I. Husain, Nigah, S. Ansari, Kiran, Umer, M. Ansari, Khan, M. O. Husain, Naqvi, Rajput, Sherzad, Siddiqui, Tahir, Wang, N. Husain, I. Chaudhry, Mulsant.</p><p><italic toggle="yes">Statistical analysis:</italic> M. I. Husain, Nigah, S. Ansari, Naqvi, Wang, N. Husain.</p><p><italic toggle="yes">Obtained funding:</italic> M. I. Husain, N. Husain, N. Chaudhry.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> M. I. Husain, Nigah, Khoso, Kiran, Umer, M. Ansari, M. O. Husain, Qadir, Rajput, Saqib, Ilyas, Doutani, Siddiqui, Tahir, N. Husain, Mulsant.</p><p><italic toggle="yes">Supervision:</italic> M. I. Husain, Khoso, Kiran, M. Ansari, Bhatia, Malik, Sherzad, N. Husain, N. Chaudhry, I. Chaudhry, Mulsant.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr M. I. Husain reported receiving support as the Tier 2 Canada Research Chair from the Canadian Institutes of Health Research (CIHR) and grants from the University of Toronto during the conduct of the study and contracted research funding from COMPASS Pathfinder Limited outside the submitted work. Dr N. Husain reported previously serving as a trustee of the Pakistan Institute of Living and Learning (PILL), Abaseen Foundation UK, Lancashire Mind UK, and Manchester Global Foundation; being an executive member of the Academic Faculty at the Royal College of Psychiatrists, London; and receiving grants from the Stanly Medical Institute, National Institute of Health Research (NIHR), Wellcome Trust, UK Research and Innovation, and Grand Challenges Canada (GCC) outside the submitted work. Dr N. Chaudhry reported receiving grants from PILL and the Department of Psychiatry, University of Toronto during the conduct of the study; being the chief executive officer of PILL, visiting professor of psychiatry at Dow University of Health Sciences, associate director of the Manchester Global Mental Health and Cultural Psychiatry Group, and visiting senior scientist at the Manchester Global Foundation; and receiving research grants from organizations such as the NIHR, GCC, the Higher Education Commission, the CIHR, and the Wellcome Trust outside the submitted work. Dr Mulsant reported being the Labatt Family Chair, Department of Psychiatry, at the University of Toronto during the conduct of the study and the Senior Scientist at the Centre for Addiction and Mental Health outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This study was supported in part by funding for the Tier 2 Canada Research Chair from the CIHR (Dr M. I. Husain).</p><p><bold>Role of the Funder/Sponsor:</bold> The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI250830-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-09-02T10:00"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>8</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496127</issue-id><elocation-id>e2529427</elocation-id><history><date date-type="received"><day>3</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>7</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2025 Husain MI et al. <italic toggle="yes">JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jamanetwopen-e2529427.pdf"/><self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2529427.pdf">jamanetwopen-e2529427.pdf</self-uri><self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.29427"/><related-article related-article-type="commentary" xml:lang="en" journal-id="JAMA Netw Open" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40892417"><article-title>Speeding Up Response Time for Antidepressive Treatment.</article-title><volume>8</volume><issue>9</issue><date><day>2</day><month>9</month><year>2025</year></date><fpage>e2529440</fpage><lpage>e2529440</lpage><source>JAMA Netw Open</source><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2025.29440</pub-id><pub-id pub-id-type="pmid">40892417</pub-id></related-article><abstract abstract-type="teaser" specific-use="electronic"><p>This randomized clinical trial evaluates whether adults receiving measurement-based care vs standard care for major depressive disorder have faster response and remission times.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-zoi250830-1"><title>Question</title><p>Does measurement-based care (MBC) reduce time to response and time to remission compared with standard care for major depressive disorder (MDD) in a low- and middle-income country such as Pakistan?</p></sec><sec id="ab-zoi250830-2"><title>Findings</title><p>In a randomized clinical trial of 154 adults with nonpsychotic MDD, the time to response and time to remission were half as long among those who received MBC compared with those who received standard care.</p></sec><sec id="ab-zoi250830-3"><title>Meaning</title><p>Findings of this trial indicate that MBC may improve treatment outcomes for MDD in resource-limited settings such as Pakistan.</p></sec></abstract><abstract><sec id="ab-zoi250830-4"><title>Importance</title><p>Measurement-based care (MBC) guides clinical decisions through structured monitoring of symptoms and adverse effects. Although MBC has been associated with improved outcomes in major depressive disorder (MDD), its effectiveness in low- and middle-income countries (LMICs) remains understudied.</p></sec><sec id="ab-zoi250830-5"><title>Objective</title><p>To assess whether MBC accelerates the resolution of depressive symptoms compared with standard care among adults with MDD in Pakistan.</p></sec><sec id="ab-zoi250830-6"><title>Design, Setting, and Participants</title><p>This multicenter, assessor-blinded, parallel-arm randomized clinical trial was conducted in Pakistan from September 2022 to January 2024, with 24 weeks of follow-up. Adults diagnosed with nonpsychotic MDD were recruited from psychiatric hospitals and primary care centers in 7 Pakistani cities (Karachi, Lahore, Rawalpindi, Hyderabad, Peshawar, Multan, and Quetta). Participants were randomized 1:1 to MBC or standard care. Intention-to-treat analyses were conducted.</p></sec><sec id="ab-zoi250830-7"><title>Interventions</title><p>By design, pharmacotherapy was limited to paroxetine or mirtazapine in both MBC or standard care groups. The MBC group completed the 16-item Quick Inventory of Depressive Symptomatology&#8211;Self-Report and the Frequency, Intensity, and Burden of Side Effects Rating Scale at each visit (baseline and weeks 2, 4, 8, 12, and 24). Scores from these instruments informed antidepressant dose adjustments or switch. The standard care group received treatment based on clinician judgment and did not undergo repeated clinical measurements.</p></sec><sec id="ab-zoi250830-8"><title>Main Outcomes and Measures</title><p>Primary outcomes were time to response (defined as &#8805;50% reduction in the 17-item Hamilton Depression Rating Scale [HDRS-17]; range: 0-52, with the highest score indicating severe depression) and time to remission (defined as HDRS-17 score of &#8804;7) within the 24-week follow-up period. Secondary outcomes included changes in HDRS-17 scores and rates of adverse effects or treatment discontinuation.</p></sec><sec id="ab-zoi250830-9"><title>Results</title><p>A total of 154 adults (mean [SD] age, 34.5 [10.5] years; 105 females [68.2%]) were randomized. Median (IQR) time to response was faster with MBC than with standard care (2 [2-4] weeks vs 4 [2-12] weeks); similarly, median (IQR) time to remission was faster for MBC vs standard care (4 [4-8] weeks vs 8 weeks [2 weeks to no remission] weeks). At week 24, there were no significant differences in rates of response or remission between groups. After week 24, reduction in mean HDRS-17 scores was significantly but modestly greater in the MBC group than in the standard care group (&#8722;18.1 [95% CI, 16.4-19.6] points vs &#8722;17.0 [95% CI, 15.6-18.5] points; <italic toggle="yes">t</italic><sub>129</sub>&#8201;=&#8201;0.71; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001). No differences were observed in other secondary outcomes.</p></sec><sec id="ab-zoi250830-10"><title>Conclusions and Relevance</title><p>This trial of adults with MDD found that MBC led to faster time to response and time to remission than standard care in low-resource settings. Future studies need to confirm the clinical effectiveness of MBC and assess its cost-effectiveness in LMICs.</p></sec><sec id="ab-zoi250830-11"><title>Trial Registration</title><p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT05431374?intr=NCT05431374&amp;rank=1" ext-link-type="uri">NCT05431374</ext-link></p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-ZOI250830"><title>Introduction</title><p>Major depressive disorder (MDD) is a leading cause of disability across populations and settings.<sup><xref rid="zoi250830r1" ref-type="bibr">1</xref></sup> The global incidence of MDD has increased over the past 3 decades,<sup><xref rid="zoi250830r2" ref-type="bibr">2</xref></sup> with the current prevalence being higher in low- and middle-income countries (LMICs) than in high-income countries (HICs).<sup><xref rid="zoi250830r3" ref-type="bibr">3</xref></sup> Despite access to effective pharmacotherapy and psychotherapy in HICs, only a third of patients with MDD achieve remission.<sup><xref rid="zoi250830r4" ref-type="bibr">4</xref></sup> Inadequate antidepressant dose and duration of antidepressant trials have been identified as the main causes for poor outcomes.<sup><xref rid="zoi250830r5" ref-type="bibr">5</xref></sup></p><p>Over the past decade, measurement-based care (MBC) has been proposed as a solution to this challenge. MBC is a simple intervention for use of antidepressants that is based on regular monitoring and applies validated clinical instruments to guide treatment decisions.<sup><xref rid="zoi250830r6" ref-type="bibr">6</xref></sup> While there is evidence of the effectiveness of MBC in the management of MDD in HICs<sup><xref rid="zoi250830r7" ref-type="bibr">7</xref></sup> and some upper middle&#8211;income countries, such as China,<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> we are not aware of any evaluations of MBC in LMICs. Given the high prevalence of MDD and the lack of access to specialized psychiatric services in these settings, MBC may offer a scalable approach to enhance outcomes for patients with MDD in LMICs. In this context, we conducted a randomized clinical trial (RCT) comparing MBC vs standard care for MDD in Pakistan. Time to response and time to remission were chosen as the primary outcomes to assess whether MBC accelerates the resolution of depressive symptoms among adults with MDD as this is important in low-resource settings (eg, LMICs), where access to care and treatment options are limited. We hypothesized that MBC would lead to faster antidepressant response and symptom remission than standard care.</p></sec><sec id="H1-2-ZOI250830"><title>Methods</title><p>This multicenter, assessor-blinded, parallel-arm RCT was conducted in Pakistan between September 2022 and January 2024, replicating the design of a trial by Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> conducted in Beijing, China. Antidepressants were fixed to paroxetine or mirtazapine in both treatment groups to minimize heterogeneity in outcomes due to variability in response to and tolerability of specific antidepressants<sup><xref rid="zoi250830r9" ref-type="bibr">9</xref></sup> and to allow the isolation of the effects of MBC. Doses were converted to amitriptyline equivalents (ie, 10-mg paroxetine or 15-mg mirtazapine&#8201;=&#8201;50-mg amitriptyline). Pakistan&#8217;s National Bioethics Committee approved this trial; the trial protocol is available in <xref rid="note-ZOI250830-1-s" ref-type="supplementary-material">Supplement 1</xref>. All participants provided written informed consent. We followed the Consolidated Standards of Reporting Trials (<ext-link xlink:href="http://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) reporting guideline.<sup><xref rid="zoi250830r10" ref-type="bibr">10</xref></sup></p><sec id="H2-1-ZOI250830"><title>Participants and Settings</title><p>Participants were recruited from outpatient departments in general and psychiatric hospitals or primary care clinics and Basic Health Units in 7 major cities in Pakistan: Karachi (23 million), Lahore (10 million), Rawalpindi (3 million), Hyderabad (2 million), Peshawar (2 million), Multan (1.8 million), and Quetta (1 million). These urban locations represent a combined population of more than 42 million people (out of 236 million Pakistanis) and serve as hubs for both public and private mental health care.</p><p>Participants were adult outpatients aged 18 to 65 years with nonpsychotic MDD (diagnosed by their treating physicians and confirmed using a checklist based on the <italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition</italic> [<italic toggle="yes">DSM-5</italic>] criteria at screening), a score of 18 or higher (indicating moderate to severe depression) on the 17-item Hamilton Depression Rating (HDRS-17), and the ability to speak English or Urdu fluently and to provide written informed consent. Potential participants were excluded if they had a lifetime diagnosis of bipolar, psychotic, obsessive-compulsive, eating, or substance use (excluding nicotine) disorder based on the <italic toggle="yes">DSM-5</italic> criteria; a history of a lack of response or intolerance to paroxetine or mirtazapine; a suicide attempt during the current depressive episode; any physical condition contraindicating the use of paroxetine or mirtazapine; or were pregnant or breastfeeding.</p></sec><sec id="H2-2-ZOI250830"><title>Sample Size</title><p>The target sample size replicated the sample size of the Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> trial. Anticipating a 20% dropout rate, we aimed to randomize 150 participants to obtain 120 completers. Given the lack of robust data on expected differences in time to remission in LMICs, as Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> used, we relied on estimates of remission rates to calculate the power based on the sample size. With a difference of 45% in remission rates (ie, 74% MBC vs 29% standard care in the Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> trial), 120 completers provided greater than 99% power at &#945;&#8201;=&#8201;.05 to detect a difference in remission rates. Even with a smaller effect size of 18% (ie, 59% vs 41% in the Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> trial), power remained greater than 80%.<sup><xref rid="zoi250830r11" ref-type="bibr">11</xref></sup></p></sec><sec id="H2-3-ZOI250830"><title>Randomization and Masking</title><p>Participants were randomized 1:1 to MBC or standard care (<xref rid="zoi250830f1" ref-type="fig">Figure 1</xref>) using 14 computer-generated lists with random permuted blocks, stratified by site and self-reported sex at birth. Given the nature of the intervention, physicians and participants were not masked to treatment allocation, but all of the outcome assessors were. Participants were instructed not to disclose their treatment group to outcome assessors, and new assessors were assigned if unintentional unblinding occurred.</p><fig position="float" id="zoi250830f1" fig-type="figure" orientation="portrait"><label>Figure 1. </label><caption><title>Participant Flow Diagram</title><p>HDRS-17 indicates the 17-item Hamilton Depression Rating Scale (range: 0-52, with the highest score indicating severe depression).</p></caption><graphic position="float" orientation="portrait" xlink:href="jamanetwopen-e2529427-g001.jpg"/></fig></sec><sec id="H2-4-ZOI250830"><title>Interventions and Procedures</title><p>After providing informed consent, participants entered a 1-week washout phase to minimize the effects of psychotropic medications previously taken. After the washout week, the participants were assigned randomly to either the MBC group or the standard care group. Regardless of their treatment group, participants received either open-label paroxetine (10-60 mg/d) or open-label mirtazapine (7.5-45 mg/d). All patients were followed up for 24 weeks after randomization, with research assessments at baseline and weeks 2, 4, 8, 12, and 24.</p><p>Starting doses were permitted to be lower than those used in the Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> trial in response to feedback from the Trial Steering Committee about patient preference for slower medication titration in the local population. In both treatment groups, the treating physician (ie, general practitioner or psychiatrist) was responsible for decisions about the prescription of paroxetine or mirtazapine and dose adjustments. One medication change between paroxetine and mirtazapine was permitted. Short-acting benzodiazepines could be prescribed occasionally for agitation, anxiety, or insomnia. Changes in antidepressant or concomitant treatment (either pharmacotherapy or psychotherapy) were recorded by the research staff at each visit.</p><sec id="H3-1-ZOI250830"><title>MBC Intervention</title><p>At every outpatient visit, participant symptoms and adverse effects were recorded through the 16-item Quick Inventory of Depressive Symptomatology&#8211;Self-Report (QIDS-SR16)<sup><xref rid="zoi250830r12" ref-type="bibr">12</xref></sup> and the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) Scale.<sup><xref rid="zoi250830r13" ref-type="bibr">13</xref></sup> The QIDS-SR16 was used to measure depressive symptoms in the past week; it has a score range of 0 to 27, with higher scores indicating higher severity.<sup><xref rid="zoi250830r12" ref-type="bibr">12</xref></sup> An elevated QIDS-SR16 total score was indicative of current treatment being unhelpful and requiring an increase of dose or a switch in medication depending on the week of treatment.<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> The FIBSER Scale was completed to evaluate antidepressants&#8217; adverse effects, their frequency, intensity, and burden.<sup><xref rid="zoi250830r13" ref-type="bibr">13</xref>,<xref rid="zoi250830r14" ref-type="bibr">14</xref></sup> A FIBSER Scale total score higher than 4 on a scale of 0 to 18 was indicative of current treatment being poorly tolerated and requiring a change of dose or a switch in medication.<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup></p><p>Participant responses on these self-reported measures informed and guided the physicians&#8217; decisions. Following a stepwise approach, a treatment protocol outlined recommended dose adjustments or medication switches needed to reduce depressive symptoms (reported on the QIDS-SR16) or to mitigate adverse effects (reported on the FIBSER Scale) (eTable 1 in <xref rid="note-ZOI250830-1-s" ref-type="supplementary-material">Supplement 2</xref>). Treating physicians underwent a 2-day training on this MBC protocol. In addition, a coordinator was designated at each study site to serve as an MBC coordinator and to facilitate adherence with the MBC treatment protocol. After each clinical visit, this coordinator compared the physician&#8217;s clinical notes with the MBC guidelines. When deviations were identified, the physician was promptly notified and encouraged to adjust the treatment accordingly.</p></sec><sec id="H3-2-ZOI250830"><title>Standard Care Control</title><p>Local medical, psychiatric, and general practitioner services provided routine care according to their clinical judgment and available resources. Standard care was directed by the participant&#8217;s treating physician based solely on clinical needs (ie, clinical measures were not obtained, and treatment protocol was not established). Research staff recorded the nature and intensity of standard care delivered to each participant. In current practice in Pakistan, standard care of MDD largely consists of pharmacotherapy, and patients with MDD are not routinely referred for any psychological therapies.</p></sec></sec><sec id="H2-5-ZOI250830"><title>Outcomes</title><p>A case report form was designed to collect sociodemographic and clinical characteristics from the sites&#8217; health records, and this information was confirmed during a clinical interview. HDRS-17 scores (range: 0-52, with the highest score indicating severe depression) obtained at baseline and each visit (at weeks 2, 4, 8, 12, and 24) were used to inform 2 primary outcomes measures: estimated time from randomization to response (defined as &#8805;50% reduction in HDRS-17 scores from baseline) and estimated time to remission (defined as a HDRS-17 score of &#8804;7).<sup><xref rid="zoi250830r15" ref-type="bibr">15</xref></sup> Secondary outcomes included adherence at each treatment visit (based on pill counts), rates of response and remission, changes in the severity of depressive symptoms (ie, change in HDRS-17 score), and time to discontinuation from the study from all causes. In addition, using a checklist, 6 common adverse effects (dry mouth, diarrhea or constipation, dizziness or drowsiness, loss of appetite or nausea, headache, and excessive sweating) were assessed at baseline and each treatment visit.</p><p>At each study site, all outcome measures were collected by 2 experienced assessors who were blind to the treatment group. The MBC coordinator at each site reminded participants at each visit about nondisclosure of their intervention group to the assessor.</p></sec><sec id="H2-6-ZOI250830"><title>Statistical Analysis</title><p>Full intention-to-treat analyses were conducted. Time-to-event outcomes (response, remission, and all-cause discontinuation) were analyzed using Kaplan-Meier survival curves. Between-group differences were assessed using the log-rank test and Cox proportional hazards regression model. The Cox model was adjusted for age, marital status, and baseline HDRS-17 scores to account for potential confounding. Rates of adherence, response, remission, and adverse effects were compared with &#967;<sup>2</sup> tests. Baseline HDRS-17 scores, antidepressant doses, number of clinic visits, changes in HDRS-17 at week 24, and number of adverse effects were compared with independent, 2-tailed <italic toggle="yes">t</italic> tests or Mann-Whitney tests, as appropriate. The significance threshold was 2-tailed <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.05 for all analyses. All analyses were conducted using SPSS for Windows, version 20.0 (IBM Corp).</p></sec></sec><sec id="H1-3-ZOI250830"><title>Results</title><p>Between September 2022 and January 2024, 351 patients were screened and 166 met eligibility criteria. Of those eligible, 154 were randomly assigned to MBC (n&#8201;=&#8201;76) or standard care (n&#8201;=&#8201;78) (<xref rid="zoi250830f1" ref-type="fig">Figure 1</xref>). The 2 groups appeared similar in baseline sociodemographic and clinical characteristics (<xref rid="zoi250830t1" ref-type="table">Table 1</xref>). Overall, patients included 105 females (68.2%) and 49 males (31.8%), with a mean (SD) age of 34.5 (10.5) years.</p><table-wrap position="float" id="zoi250830t1" orientation="portrait"><label>Table 1. </label><caption><title>Baseline Demographic and Clinical Characteristics of Participants Receiving Measurement-Based Care or Standard Care for Major Depressive Disorder</title></caption><table frame="hsides" rules="groups"><col width="32.12%" span="1"/><col width="23.11%" span="1"/><col width="23.42%" span="1"/><col width="21.35%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Participants, No. (%)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Overall sample (N&#8201;=&#8201;154)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">MBC group (n&#8201;=&#8201;76)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Standard care group (n&#8201;=&#8201;78)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">105 (68.2)</td><td valign="top" align="left" rowspan="1" colspan="1">50 (65.8)</td><td valign="top" align="left" rowspan="1" colspan="1">55 (70.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">49 (31.8)</td><td valign="top" align="left" rowspan="1" colspan="1">26 (34.2)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (29.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Family system: nuclear</td><td valign="top" align="left" rowspan="1" colspan="1">95 (61.7)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (60.5)</td><td valign="top" align="left" rowspan="1" colspan="1">49 (62.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Marital status: married</td><td valign="top" align="left" rowspan="1" colspan="1">108 (70.1)</td><td valign="top" align="left" rowspan="1" colspan="1">56 (73.7)</td><td valign="top" align="left" rowspan="1" colspan="1">52 (66.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Socioeconomic status: lower income</td><td valign="top" align="left" rowspan="1" colspan="1">86 (55.8)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (60.5)</td><td valign="top" align="left" rowspan="1" colspan="1">40 (51.3)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Initial antidepressant</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Paroxetine</td><td valign="top" align="left" rowspan="1" colspan="1">104 (67.5)</td><td valign="top" align="left" rowspan="1" colspan="1">42 (55.3)</td><td valign="top" align="left" rowspan="1" colspan="1">62 (79.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mirtazapine</td><td valign="top" align="left" rowspan="1" colspan="1">50 (32.5)</td><td valign="top" align="left" rowspan="1" colspan="1">34 (44.7)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (20.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td><td valign="top" align="left" rowspan="1" colspan="1">34.5 (10.5)</td><td valign="top" align="left" rowspan="1" colspan="1">35.7 (11.2)</td><td valign="top" align="left" rowspan="1" colspan="1">33.2 (9.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No. of years of education, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">7.0 (5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7.0 (6.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7.0 (5.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Family members in household, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">7.0 (4.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7.0 (4.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7.0 (4.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Annual participant income, median (IQR), US $</td><td valign="top" align="left" rowspan="1" colspan="1">1128 (902-1522)</td><td valign="top" align="left" rowspan="1" colspan="1">1128 (924-1748)</td><td valign="top" align="left" rowspan="1" colspan="1">902 (722-1353)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Annual household income, median (IQR), US $</td><td valign="top" align="left" rowspan="1" colspan="1">1353 (902-2255)</td><td valign="top" align="left" rowspan="1" colspan="1">1961 (1128-3382)</td><td valign="top" align="left" rowspan="1" colspan="1">1128 (902-1917)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Time since MDD diagnosis, median (IQR), wk</td><td valign="top" align="left" rowspan="1" colspan="1">52 (13-156)</td><td valign="top" align="left" rowspan="1" colspan="1">52 (22-176)</td><td valign="top" align="left" rowspan="1" colspan="1">52 (11-104)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: MBC, measurement-based care; MDD, major depressive disorder.</p></table-wrap-foot></table-wrap><p>Mean (SD) antidepressant doses (in amitriptyline equivalents) were significantly higher in the MBC group than in the standard care group at weeks 8 (153.9 [134.0] mg/d vs 112.7 [52.4] mg/d; <italic toggle="yes">P</italic>&#8201;=&#8201;.02), 12 (153.9 [133.1] mg/d vs 113.6 [52.3] mg/d; <italic toggle="yes">P</italic>&#8201;=&#8201;.03), and 24 (152.3 [134.1] mg/d vs 113.8 [52.6] mg/d; <italic toggle="yes">P</italic>&#8201;=&#8201;.04) (<xref rid="zoi250830t2" ref-type="table">Table 2</xref>). Treatment adherence, as measured by percentages of pills consumed based on pill counts, was high and similar at all points except at weeks 6 and 12 (eTable 2 in <xref rid="note-ZOI250830-1-s" ref-type="supplementary-material">Supplement 2</xref>). The number of clinic visits was significantly higher in the MBC group from week 5 to week 12, with a median (IQR) of 2 (2-2) visits in the MBC group and 1 (1-2) visit in the standard care group (<xref rid="zoi250830t2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="zoi250830t2" orientation="portrait"><label>Table 2. </label><caption><title>Antidepressant Doses and Hamilton Depression Rating Scale Scores for Participants Receiving Measurement-Based Care or Standard Care for Major Depressive Disorder</title></caption><table frame="hsides" rules="groups"><col width="31.75%" span="1"/><col width="33.58%" span="1"/><col width="24.56%" span="1"/><col width="10.11%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Outcome</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Mean (SD)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic toggle="yes">P</italic> value</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">MBC group (n&#8201;=&#8201;76)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Standard care group (n&#8201;=&#8201;78)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">
<bold>Baseline</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HDRS-17 score</td><td valign="top" align="left" rowspan="1" colspan="1">24.1 (5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">23.4 (4.3)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">
<bold>Wk 2</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No.</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="left" rowspan="1" colspan="1">72</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dose, mg/d</td><td valign="top" align="left" rowspan="1" colspan="1">96.3 (57.5)</td><td valign="top" align="left" rowspan="1" colspan="1">98.3 (62.6)</td><td valign="top" align="left" rowspan="1" colspan="1">.85</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HDRS-17 score</td><td valign="top" align="left" rowspan="1" colspan="1">12.2 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">14.6 (8.9)</td><td valign="top" align="left" rowspan="1" colspan="1">.05</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Visits from baseline to wk 2, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1-1)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1-1)</td><td valign="top" align="left" rowspan="1" colspan="1">.99</td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">
<bold>Wk 4</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No.</td><td valign="top" align="left" rowspan="1" colspan="1">66</td><td valign="top" align="left" rowspan="1" colspan="1">71</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dose, mg/d</td><td valign="top" align="left" rowspan="1" colspan="1">130.3 (112.9)</td><td valign="top" align="left" rowspan="1" colspan="1">112.3 (53.8)</td><td valign="top" align="left" rowspan="1" colspan="1">.24</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HDRS-17 score</td><td valign="top" align="left" rowspan="1" colspan="1">8.3 (4.9)</td><td valign="top" align="left" rowspan="1" colspan="1">12.6 (8.1)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Visits from wk 3 to wk 4, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1-1)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1-1)</td><td valign="top" align="left" rowspan="1" colspan="1">.99</td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">
<bold>Wk 8</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No.</td><td valign="top" align="left" rowspan="1" colspan="1">64</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dose, mg/d</td><td valign="top" align="left" rowspan="1" colspan="1">153.9 (134.0)</td><td valign="top" align="left" rowspan="1" colspan="1">112.7 (52.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HDRS-17 score</td><td valign="top" align="left" rowspan="1" colspan="1">7.7 (5.2)</td><td valign="top" align="left" rowspan="1" colspan="1">10.4 (7.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Visits from wk 5 to wk 8, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (2-2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1-2)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">
<bold>Wk 12</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No.</td><td valign="top" align="left" rowspan="1" colspan="1">64</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dose, mg/d</td><td valign="top" align="left" rowspan="1" colspan="1">153.9 (133.1)</td><td valign="top" align="left" rowspan="1" colspan="1">113.6 (52.3)</td><td valign="top" align="left" rowspan="1" colspan="1">.03</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HDRS-17 score</td><td valign="top" align="left" rowspan="1" colspan="1">6.9 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1">9.2 (6.9)</td><td valign="top" align="left" rowspan="1" colspan="1">.04</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Visits from wk 9 to wk 12, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (2-2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1-2)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">
<bold>Wk 24</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No.</td><td valign="top" align="left" rowspan="1" colspan="1">64</td><td valign="top" align="left" rowspan="1" colspan="1">67</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dose, mean (SD), mg/d</td><td valign="top" align="left" rowspan="1" colspan="1">152.3 (134.1)</td><td valign="top" align="left" rowspan="1" colspan="1">113.8 (52.6)</td><td valign="top" align="left" rowspan="1" colspan="1">.04</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">HDRS-17 score, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">5.6 (4.2)</td><td valign="top" align="left" rowspan="1" colspan="1">6.7 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">.14</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Visits from wk 13 to wk 24, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1-1)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1-1)</td><td valign="top" align="left" rowspan="1" colspan="1">.99</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: HDRS-17, 17-item Hamilton Depression Rating Scale; MBC, measurement-based care; NA, not applicable.</p></table-wrap-foot></table-wrap><p>The median (IQR) time to response was 2 (2-4) weeks in the MBC group and 4 (2-12) weeks in the standard care group. The median (IQR) time to remission was 4 (4-8) weeks in the MBC group and 8 weeks (2 weeks to no remission) in the standard care group. The estimated time intervals for response and remission in the 2 groups in the Kaplan-Meier analysis are illustrated in <xref rid="zoi250830f2" ref-type="fig">Figure 2</xref>. The difference between the survival curves was significant for both time to response (log rank test, &#967;<sup>2</sup><sub>1</sub>&#8201;=&#8201;10.21; <italic toggle="yes">P</italic>&#8201;=&#8201;.001) and time to remission (&#967;<sup>2</sup><sub>1</sub>&#8201;=&#8201;11.08; <italic toggle="yes">P</italic>&#8201;=&#8201;.001). In the Cox proportional hazards regression model, the likelihood of response (hazard ratio [HR], 1.53; 95% CI, 1.06-2.20; <italic toggle="yes">P</italic>&#8201;=&#8201;.02) and remission (HR, 1.80; 95% CI, 1.21-2.68; <italic toggle="yes">P</italic>&#8201;=&#8201;.004) were significantly higher in the MBC group than in the standard care group.</p><fig position="float" id="zoi250830f2" fig-type="figure" orientation="portrait"><label>Figure 2. </label><caption><title>Kaplan-Meier Survival Curve for Time to Response and Time to Remission by Treatment Group</title></caption><graphic position="float" orientation="portrait" xlink:href="jamanetwopen-e2529427-g002.jpg"/></fig><p>After week 24, the response rates were 89.1% in the MBC group and 86.6% in the standard care group (&#967;<sup>2</sup><sub>1</sub>&#8201;=&#8201;0.19; <italic toggle="yes">P</italic>&#8201;=&#8201;.79), for an overall response rate of 87.8%. The remission rates were 73.4% in the MBC group and 62.7% in the standard care group (&#967;<sup>2</sup><sub>1</sub>&#8201;=&#8201;1.74; <italic toggle="yes">P</italic>&#8201;=&#8201;.20), for an overall remission rate of 67.9%. After week 24, the reduction in mean HDRS-17 scores was larger in the MBC group than in the standard care group (&#8722;18.1 [95% CI, 16.4-19.6] points vs &#8722;17.0 [95% CI, 15.6-18.5] points; <italic toggle="yes">t</italic><sub>129</sub>&#8201;=&#8201;0.71; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001) (<xref rid="zoi250830t3" ref-type="table">Table 3</xref>)</p><table-wrap position="float" id="zoi250830t3" orientation="portrait"><label>Table 3. </label><caption><title>Efficacy Outcomes for Participants Receiving Measurement-Based Care or Standard Care for Major Depressive Disorder</title></caption><table frame="hsides" rules="groups"><col width="37.2%" span="1"/><col width="31.21%" span="1"/><col width="21.46%" span="1"/><col width="10.13%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Measure</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Participants, No. (%)</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic toggle="yes">P</italic> value</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">MBC group</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Standard care group</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Response</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Wk 12</td><td valign="top" align="left" rowspan="1" colspan="1">58 (90.6)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (67.6)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Wk 24 </td><td valign="top" align="left" rowspan="1" colspan="1">57 (89.1)</td><td valign="top" align="left" rowspan="1" colspan="1">58 (86.6)</td><td valign="top" align="left" rowspan="1" colspan="1">.79</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Remission</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Wk 12 </td><td valign="top" align="left" rowspan="1" colspan="1">46 (71.9)</td><td valign="top" align="left" rowspan="1" colspan="1">35 (51.5)</td><td valign="top" align="left" rowspan="1" colspan="1">.02</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Wk 24 </td><td valign="top" align="left" rowspan="1" colspan="1">47 (73.4)</td><td valign="top" align="left" rowspan="1" colspan="1">42 (62.7)</td><td valign="top" align="left" rowspan="1" colspan="1">.20</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Estimated time to response, median (IQR), wk</td><td valign="top" align="left" rowspan="1" colspan="1">2 (2-4)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (2-12)</td><td valign="top" align="left" rowspan="1" colspan="1">.001<xref rid="zoi250830t3n1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Estimated time to remission, median (IQR), wk</td><td valign="top" align="left" rowspan="1" colspan="1">4 (4-8)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (2-NR)<xref rid="zoi250830t3n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">.001<xref rid="zoi250830t3n1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Change in HDRS-17 score, mean (95% CI), points</td><td valign="top" align="left" rowspan="1" colspan="1">18.1 (16.4-19.6)</td><td valign="top" align="left" rowspan="1" colspan="1">17.0 (15.6-18.5)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: HDRS-17, 17-item Hamilton Depression Rating Scale; MBC, measurement-based care; NR, no remission.</p><fn id="zoi250830t3n1"><label>
<sup>a</sup>
</label><p>Difference between survival curve of Kaplan-Meier analysis.</p></fn><fn id="zoi250830t3n2"><label>
<sup>b</sup>
</label><p>No remission within the follow-up period of 24 weeks.</p></fn></table-wrap-foot></table-wrap><p>In the Kaplan-Meier analysis of all-cause discontinuation, the difference between the survival curves in both groups was not significant (&#967;<sup>2</sup><sub>1</sub>&#8201;=&#8201;0.10; <italic toggle="yes">P</italic>&#8201;=&#8201;.70) (eFigure in <xref rid="note-ZOI250830-1-s" ref-type="supplementary-material">Supplement 2</xref>). The number and frequency of any type of adverse events were similar across both groups (eTable 3 in <xref rid="note-ZOI250830-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p></sec><sec id="H1-4-ZOI250830"><title>Discussion</title><p>This RCT compared the outcomes of MBC and standard care for the pharmacotherapy of MDD in Pakistan. The results support that MBC, including a sequential treatment protocol with MBC coordinators facilitating physicians&#8217; adherence to this protocol, can be successfully integrated into clinical practice and improve patient outcomes in an LMIC, such as Pakistan. Time to response and time to remission were significantly shorter in the MBC group than in the standard care group. These results confirm and extend the results of a previous trial conducted by Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> in China. They are clinically meaningful, as they suggest that MBC reduces the duration of depressive symptoms in an LMIC.</p><p>There were a higher number of clinic visits and higher antidepressant doses in the MBC group, without a higher frequency of treatment discontinuation or adverse effects. Similar to the Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> trial, the higher doses in the first 4 weeks of treatment may have led to faster symptom reduction in the MBC group. Inadequate antidepressant doses have been shown to contribute to poor outcomes in a subgroup of patients with MDD.<sup><xref rid="zoi250830r16" ref-type="bibr">16</xref></sup> The significantly higher rates of response and remission in the MBC group at week 12 support an earlier assertive approach to treatment of MDD. The similar rates of treatment discontinuation and adverse effects in the 2 treatment groups also indicate that a higher burden of adverse effects did not compromise the more assertive antidepressant treatment in the MBC group.</p><p>The results of both our primary outcomes (ie, time to response and time to remission) and early secondary outcomes (ie, rate of response and rate of remission at week 12) are congruent with the findings of the Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> trial, with almost identical rates of remission in the MBC group at week 12 (73.4% in the present trial vs 73.8% in Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup>). By contrast, in the current trial, rates of response and remission were no longer significantly different at week 24, when the rate of remission in the standard care group had increased to 62.7% (vs 28.8% in the Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> trial). Differences in study setting and populations may explain this discrepancy. The Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> trial was conducted in a large urban university&#8211;affiliated teaching hospital in Beijing, China, whereas the present trial was conducted across several Pakistani cities, in clinics and Basic Health Units that serve large suburban and rural populations. Previous studies have shown the therapeutic effects of attentive care through repeated study visits in clinical trials,<sup><xref rid="zoi250830r17" ref-type="bibr">17</xref>,<xref rid="zoi250830r18" ref-type="bibr">18</xref>,<xref rid="zoi250830r19" ref-type="bibr">19</xref></sup> with each additional visit contributing to further symptom improvement.<sup><xref rid="zoi250830r20" ref-type="bibr">20</xref></sup> While participants in the control group did not complete repeated clinical measures of their depressive symptoms or adverse effects, they completed repeated research assessments of their symptoms, which may also have contributed to their high response and remission rates.<sup><xref rid="zoi250830r21" ref-type="bibr">21</xref></sup> These nonspecific therapeutic effects may be particularly relevant in low-resource settings, such as Pakistan, where more than 90% of individuals (particularly those in suburban or rural areas) do not have access to evidence-based mental health care.<sup><xref rid="zoi250830r22" ref-type="bibr">22</xref></sup></p><p>In addition to repeated monitoring of their clinical symptoms and adverse effects, participants in the MBC group may have benefited from the MBC treatment protocol and MBC coordinators who facilitated physician adherence to this protocol. The timely feedback the coordinators provided to physicians treating participants in the MBC group likely helped to overcome common barriers, such as clinical inertia. This benefit highlights that successful deployment of MBC may require not only structured clinical measurements but also dedicated personnel to facilitate implementation of treatment protocols.<sup><xref rid="zoi250830r23" ref-type="bibr">23</xref></sup></p><sec id="H2-7-ZOI250830"><title>Strengths and Limitations</title><p>Our decision to replicate a previous RCT of MBC was driven in part by the need to address what has been called the replicability crisis in mental health research.<sup><xref rid="zoi250830r24" ref-type="bibr">24</xref>,<xref rid="zoi250830r25" ref-type="bibr">25</xref>,<xref rid="zoi250830r26" ref-type="bibr">26</xref></sup> This focus allowed us to enroll a relatively modest sample size. The high retention rate (85% overall), pragmatic design, and implementation in a low-resource setting are additional strengths of this trial and enhance the generalizability of our findings. Most RCTs of pharmacotherapies, including antidepressants, are conducted in HICs, limiting their international representativeness.<sup><xref rid="zoi250830r27" ref-type="bibr">27</xref></sup></p><p>Limitations of this trial are linked to its strengths. We adopted the study design of the Guo et al<sup><xref rid="zoi250830r8" ref-type="bibr">8</xref></sup> trial in China and used the same 2 antidepressants (paroxetine and mirtazapine), which are not the antidepressants most commonly used in Pakistan or other countries.<sup><xref rid="zoi250830r28" ref-type="bibr">28</xref></sup> This replication may limit generalizability to clinical prescribing practices. We also used the same sample size that was based on expected rates of remission (ie, a secondary outcome) rather than the primary outcomes of time to response and time to remission. These outcomes were focused on depressive symptoms rather than broader measures of function or quality of life. Another limitation of the trial is the absence of a formal assessment of interrater reliability. To mitigate this gap, all blinded assessors underwent centralized training and certification prior to the study to ensure consistency in administering and scoring the HDRS-17. Regular supervision and calibration meetings were also held to minimize variability across raters. Finally, early in the trial, participants in the MBC group experienced high rates of response and remission that can be explained by the data-driven clinical decision-making and the monitoring of physician adherence to the treatment protocol in this group. Later in the trial, similar high rates of response and remission were also observed in the standard care group, possibly due to the structured nature of RCTs, including frequent follow-up visits and research assessments of symptoms. Because of these enhancements to standard care, outcomes in the standard care group may not reflect the outcomes obtained under actual clinical conditions.<sup><xref rid="zoi250830r21" ref-type="bibr">21</xref></sup></p></sec></sec><sec id="H1-5-ZOI250830"><title>Conclusions</title><p>In this trial of adults with MDD in Pakistan, MBC accelerated the time to response and time to remission compared with standard care. Given its scalable nature, MBC offers a viable solution to the need for effective mental health interventions in LMICs, where resources are often constrained and populations face substantial barriers to accessing mental health care. Future studies need to confirm the clinical effectiveness of MBC and assess its cost-effectiveness across various LMICs.</p></sec></body><back><ref-list id="REF-ZOI250830"><title>References</title><ref id="zoi250830r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Vos</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Abbafati</surname><given-names>C</given-names></string-name>, <etal/>; <collab>GBD 2019 Diseases and Injuries Collaborators</collab></person-group>. <article-title>Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>396</volume>(<issue>10258</issue>):<fpage>1204</fpage>-<lpage>1222</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30925-9</pub-id><pub-id pub-id-type="pmid">33069326</pub-id><pub-id pub-id-type="pmcid">PMC7567026</pub-id></mixed-citation></ref><ref id="zoi250830r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Liu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lyu</surname><given-names>J</given-names></string-name></person-group>. <article-title>Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease Study</article-title>. <source>J Psychiatr Res</source>. <year>2020</year>;<volume>126</volume>:<fpage>134</fpage>-<lpage>140</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpsychires.2019.08.002</pub-id><pub-id pub-id-type="pmid">31439359</pub-id></mixed-citation></ref><ref id="zoi250830r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Moitra</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Santomauro</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>PY</given-names></string-name>, <etal/></person-group>. <article-title>The global gap in treatment coverage for major depressive disorder in 84 countries from 2000-2019: a systematic review and bayesian meta-regression analysis</article-title>. <source>PLoS Med</source>. <year>2022</year>;<volume>19</volume>(<issue>2</issue>):<elocation-id>e1003901</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1003901</pub-id><pub-id pub-id-type="pmid">35167593</pub-id><pub-id pub-id-type="pmcid">PMC8846511</pub-id></mixed-citation></ref><ref id="zoi250830r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Xiao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>The effectiveness of enhanced evidence-based care for depressive disorders: a meta-analysis of randomized controlled trials</article-title>. <source>Transl Psychiatry</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>531</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41398-021-01638-7</pub-id><pub-id pub-id-type="pmid">34657142</pub-id><pub-id pub-id-type="pmcid">PMC8520525</pub-id></mixed-citation></ref><ref id="zoi250830r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jones</surname><given-names>BDM</given-names></string-name>, <string-name name-style="western"><surname>Husain</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Mulsant</surname><given-names>BH</given-names></string-name></person-group>. <article-title>The use of sequential pharmacotherapy for the treatment of acute major depression: a scoping review</article-title>. <source>Expert Opin Pharmacother</source>. <year>2021</year>;<volume>22</volume>(<issue>8</issue>):<fpage>1005</fpage>-<lpage>1014</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14656566.2021.1878144</pub-id><pub-id pub-id-type="pmid">33612048</pub-id></mixed-citation></ref><ref id="zoi250830r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lam</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Kennedy</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on clinical guidelines for management of major depressive disorder in adults: r&#233;seau canadien pour les traitements de l&#8217;humeur et de l&#8217;anxi&#233;t&#233; (CANMAT) 2023: mise &#224; jour des lignes directrices cliniques pour la prise en charge du trouble d&#233;pressif majeur chez les adultes</article-title>. <source>Can J Psychiatry</source>. <year>2024</year>;<volume>69</volume>(<issue>9</issue>):<fpage>641</fpage>-<lpage>687</lpage>. doi:<pub-id pub-id-type="doi">10.1177/07067437241245384</pub-id><pub-id pub-id-type="pmid">38711351</pub-id><pub-id pub-id-type="pmcid">PMC11351064</pub-id></mixed-citation></ref><ref id="zoi250830r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Zhu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>The efficacy of measurement-based care for depressive disorders: systematic review and meta-analysis of randomized controlled trials</article-title>. <source>J Clin Psychiatry</source>. <year>2021</year>;<volume>82</volume>(<issue>5</issue>):<fpage>37090</fpage>. doi:<pub-id pub-id-type="doi">10.4088/JCP.21r14034</pub-id><pub-id pub-id-type="pmid">34587377</pub-id></mixed-citation></ref><ref id="zoi250830r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Guo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters</article-title>. <source>Am J Psychiatry</source>. <year>2015</year>;<volume>172</volume>(<issue>10</issue>):<fpage>1004</fpage>-<lpage>1013</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ajp.2015.14050652</pub-id><pub-id pub-id-type="pmid">26315978</pub-id></mixed-citation></ref><ref id="zoi250830r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Cipriani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Furukawa</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Salanti</surname><given-names>G</given-names></string-name>, <etal/></person-group>. <article-title>Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>(<issue>10128</issue>):<fpage>1357</fpage>-<lpage>1366</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(17)32802-7</pub-id><pub-id pub-id-type="pmid">29477251</pub-id><pub-id pub-id-type="pmcid">PMC5889788</pub-id></mixed-citation></ref><ref id="zoi250830r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Butcher</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Monsour</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mew</surname><given-names>EJ</given-names></string-name>, <etal/></person-group>. <article-title>Guidelines for Reporting Outcomes in Trial Reports: the CONSORT-Outcomes 2022 Extension</article-title>. <source>JAMA</source>. <year>2022</year>;<volume>328</volume>(<issue>22</issue>):<fpage>2252</fpage>-<lpage>2264</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2022.21022</pub-id><pub-id pub-id-type="pmid">36511921</pub-id></mixed-citation></ref><ref id="zoi250830r11"><label>11</label><mixed-citation publication-type="webpage">SampSize. A tool to aid calculating sample size and power for clinical trials. Accessed January 14, 2025. <ext-link xlink:href="https://app.sampsize.org.uk/" ext-link-type="uri">https://app.sampsize.org.uk/</ext-link></mixed-citation></ref><ref id="zoi250830r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Ibrahim</surname><given-names>HM</given-names></string-name>, <etal/></person-group>. <article-title>The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression</article-title>. <source>Biol Psychiatry</source>. <year>2003</year>;<volume>54</volume>(<issue>5</issue>):<fpage>573</fpage>-<lpage>583</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0006-3223(02)01866-8</pub-id><pub-id pub-id-type="pmid">12946886</pub-id></mixed-citation></ref><ref id="zoi250830r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wisniewski</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Balasubramani</surname><given-names>GK</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Nierenberg</surname><given-names>AA</given-names></string-name>; <collab>STARD Investigators</collab></person-group>. <article-title>Self-rated global measure of the frequency, intensity, and burden of side effects</article-title>. <source>J Psychiatr Pract</source>. <year>2006</year>;<volume>12</volume>(<issue>2</issue>):<fpage>71</fpage>-<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00131746-200603000-00002</pub-id><pub-id pub-id-type="pmid">16728903</pub-id></mixed-citation></ref><ref id="zoi250830r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></string-name></person-group>. <article-title>Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission</article-title>. <source>J Clin Psychiatry</source>. <year>2009</year>;<volume>70</volume>(<issue>suppl 6</issue>):<fpage>26</fpage>-<lpage>31</lpage>. doi:<pub-id pub-id-type="doi">10.4088/JCP.8133su1c.04</pub-id><pub-id pub-id-type="pmid">19922741</pub-id></mixed-citation></ref><ref id="zoi250830r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hamilton</surname><given-names>M</given-names></string-name></person-group>. <article-title>A rating scale for depression</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>1960</year>;<volume>23</volume>(<issue>1</issue>):<fpage>56</fpage>-<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jnnp.23.1.56</pub-id><pub-id pub-id-type="pmid">14399272</pub-id><pub-id pub-id-type="pmcid">PMC495331</pub-id></mixed-citation></ref><ref id="zoi250830r16"><label>16</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>von Knorring</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Baryshnikov</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Jylh&#228;</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Talaslahti</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Heikkinen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Isomets&#228;</surname><given-names>E</given-names></string-name></person-group>. <article-title>Prospective study of antidepressant treatment of psychiatric patients with depressive disorders: treatment adequacy and outcomes</article-title>. <source>BMC Psychiatry</source>. <year>2023</year>;<volume>23</volume>(<issue>1</issue>):<fpage>888</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12888-023-05390-8</pub-id><pub-id pub-id-type="pmid">38017416</pub-id><pub-id pub-id-type="pmcid">PMC10683284</pub-id></mixed-citation></ref><ref id="zoi250830r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mulsant</surname><given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Blumberger</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Rabheru</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rapoport</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>A systematic approach to pharmacotherapy for geriatric major depression</article-title>. <source>Clin Geriatr Med</source>. <year>2014</year>;<volume>30</volume>(<issue>3</issue>):<fpage>517</fpage>-<lpage>534</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cger.2014.05.002</pub-id><pub-id pub-id-type="pmid">25037293</pub-id><pub-id pub-id-type="pmcid">PMC4122285</pub-id></mixed-citation></ref><ref id="zoi250830r18"><label>18</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Husain</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Chaudhry</surname><given-names>IB</given-names></string-name>, <string-name name-style="western"><surname>Khoso</surname><given-names>AB</given-names></string-name>, <etal/></person-group>. <article-title>Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial</article-title>. <source>Lancet Psychiatry</source>. <year>2020</year>;<volume>7</volume>(<issue>6</issue>):<fpage>515</fpage>-<lpage>527</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2215-0366(20)30138-3</pub-id><pub-id pub-id-type="pmid">32445690</pub-id></mixed-citation></ref><ref id="zoi250830r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Husain</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Chaudhry</surname><given-names>IB</given-names></string-name>, <string-name name-style="western"><surname>Khoso</surname><given-names>AB</given-names></string-name>, <etal/></person-group>. <article-title>Effect of adjunctive simvastatin on depressive symptoms among adults with treatment-resistant depression: a randomized clinical trial</article-title>. <source>JAMA Netw Open</source>. <year>2023</year>;<volume>6</volume>(<issue>2</issue>):<elocation-id>e230147</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.0147</pub-id><pub-id pub-id-type="pmid">36808239</pub-id><pub-id pub-id-type="pmcid">PMC9941891</pub-id></mixed-citation></ref><ref id="zoi250830r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Posternak</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Zimmerman</surname><given-names>M</given-names></string-name></person-group>. <article-title>Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis</article-title>. <source>Br J Psychiatry</source>. <year>2007</year>;<volume>190</volume>:<fpage>287</fpage>-<lpage>292</lpage>. doi:<pub-id pub-id-type="doi">10.1192/bjp.bp.106.028555</pub-id><pub-id pub-id-type="pmid">17401033</pub-id></mixed-citation></ref><ref id="zoi250830r21"><label>21</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ishrat Husain</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rodie</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Perivolaris</surname><given-names>A</given-names></string-name>, <etal/>; <collab>PARTNERs Study Group</collab></person-group>. <article-title>A collaborative-care telephone-based intervention for depression, anxiety, and at-risk drinking in primary care: the PARTNERs randomized clinical trial</article-title>. <source>Can J Psychiatry</source>. <year>2023</year>;<volume>68</volume>(<issue>10</issue>):<fpage>732</fpage>-<lpage>744</lpage>. doi:<pub-id pub-id-type="doi">10.1177/07067437231156243</pub-id><pub-id pub-id-type="pmid">36855791</pub-id><pub-id pub-id-type="pmcid">PMC10517649</pub-id></mixed-citation></ref><ref id="zoi250830r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Sikander</surname><given-names>S</given-names></string-name></person-group>. <article-title>Pakistan</article-title>. <source>Lancet Psychiatry</source>. <year>2020</year>;<volume>7</volume>(<issue>10</issue>):<fpage>845</fpage>. doi:<pub-id pub-id-type="doi">10.1016/S2215-0366(20)30387-4</pub-id><pub-id pub-id-type="pmid">32949518</pub-id><pub-id pub-id-type="pmcid">PMC7494296</pub-id></mixed-citation></ref><ref id="zoi250830r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Tavakoli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Husain</surname><given-names>MI</given-names></string-name>, <etal/></person-group>. <article-title>Challenges related to the implementation of measurement-based care for the treatment of major depressive disorder: a feasibility study</article-title>. <source>Pharmacopsychiatry</source>. <year>2025</year>;58(4):170-177. doi:<pub-id pub-id-type="doi">10.1055/a-2508-5757</pub-id><pub-id pub-id-type="pmid">39999977</pub-id></mixed-citation></ref><ref id="zoi250830r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ioannidis</surname><given-names>JPA</given-names></string-name></person-group>. <article-title>Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?</article-title><source>Philos Ethics Humanit Med</source>. <year>2008</year>;<volume>3</volume>:<fpage>14</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1747-5341-3-14</pub-id><pub-id pub-id-type="pmid">18505564</pub-id><pub-id pub-id-type="pmcid">PMC2412901</pub-id></mixed-citation></ref><ref id="zoi250830r25"><label>25</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Leichsenring</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Abbass</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hilsenroth</surname><given-names>MJ</given-names></string-name>, <etal/></person-group>. <article-title>Biases in research: risk factors for non-replicability in psychotherapy and pharmacotherapy research</article-title>. <source>Psychol Med</source>. <year>2017</year>;<volume>47</volume>(<issue>6</issue>):<fpage>1000</fpage>-<lpage>1011</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S003329171600324X</pub-id><pub-id pub-id-type="pmid">27955715</pub-id></mixed-citation></ref><ref id="zoi250830r26"><label>26</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Tajika</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ogawa</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Takeshima</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hayasaka</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Furukawa</surname><given-names>TA</given-names></string-name></person-group>. <article-title>Replication and contradiction of highly cited research papers in psychiatry: 10-year follow-up</article-title>. <source>Br J Psychiatry</source>. <year>2015</year>;<volume>207</volume>(<issue>4</issue>):<fpage>357</fpage>-<lpage>362</lpage>. doi:<pub-id pub-id-type="doi">10.1192/bjp.bp.113.143701</pub-id><pub-id pub-id-type="pmid">26159600</pub-id></mixed-citation></ref><ref id="zoi250830r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Chevance</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ravaud</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Cornelius</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Mayo-Wilson</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Furukawa</surname><given-names>TA</given-names></string-name></person-group>. <article-title>Designing clinically useful psychopharmacological trials: challenges and ways forward</article-title>. <source>Lancet Psychiatry</source>. <year>2022</year>;<volume>9</volume>(<issue>7</issue>):<fpage>584</fpage>-<lpage>594</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2215-0366(22)00041-4</pub-id><pub-id pub-id-type="pmid">35525252</pub-id></mixed-citation></ref><ref id="zoi250830r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kamran</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Saqlain</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the tertiary care hospital of Pakistan: a prospective approach</article-title>. <source>Expert Rev Pharmacoecon Outcomes Res</source>. <year>2022</year>;<volume>22</volume>(<issue>5</issue>):<fpage>845</fpage>-<lpage>851</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14737167.2022.2021073</pub-id><pub-id pub-id-type="pmid">34927501</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZOI250830-1"><supplementary-material id="note-ZOI250830-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p>
Trial Protocol and Statistical Analysis Plan
</p></caption><media xlink:href="jamanetwopen-e2529427-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p><bold>eTable 1</bold>. The Measurement-Based Care Schedule</p><p><bold>eTable 2.</bold> Medication Adherence as Assessed via Percentage of Pills Consumed at Each Time Point</p><p><bold>eTable 3.</bold> Adverse Effects Among Participants Receiving Measurement-Based Care or Standard Care</p><p><bold>eFigure.</bold> Estimated Median Time to Discontinuation by Kaplan-Meier Analysis</p></caption><media xlink:href="jamanetwopen-e2529427-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 3.</label><caption><p>
Data Sharing Statement
</p></caption><media xlink:href="jamanetwopen-e2529427-s003.pdf" position="float" orientation="portrait"/></supplementary-material></notes></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>